Nasdaq
$5.51▲ 1.85%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $244.3MShares out 44.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 4d agoPre-market26.10.21 13:15filedEFFECTOther#●●●#●●●
GT Biopharma, Inc.
GT Biopharma's registration statement was declared effective by the SEC on October 20, 2026. This effectiveness allows the company to proceed with the issuance or sale of the registered securities.…more
$5.51+1.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoAfter-hours26.10.21 06:20424B3Offering
GT Biopharma, Inc.
GT Biopharma has filed a registration statement for the resale of up to 13,502,835 shares of common stock, which may be issued upon the conversion of Series M and Series L preferred stock and the exercise of associated warrants. This prospectus facilitates potential sales by selling stockholders, and the company will not receive any proceeds from these transactions.…more
$5.51+1.85%vs prev closeView filingShare - 10.13After-hours26.10.14 06:00DEF 14AOther
GT Biopharma, Inc.
GT Biopharma will hold a Special Meeting of Stockholders on November 11, 2026, to vote on increasing authorized common shares from 25 million to 250 million. The meeting will also seek approval for the issuance of 19.99% or more of outstanding common stock related to the September 14, 2026, Securities Purchase Agreement, including shares issuable upon conversion of Series M Preferred Stock and exercise of warrants. These measures are intended to support corporate purposes and facilitate the conversion and exercise of existing securities.…more
$5.51+1.85%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9After-hours26.10.10 06:32Bullish#●●●
GT Biopharma Files Prospectus for Offering of Up to 13.5M Shares
GT Biopharma has filed a prospectus with the SEC regarding the potential sale of up to 13,502,835 shares by selling stockholders. This filing indicates a potential increase in the number of shares available for trading, which may lead to share dilution.…more
$5.51+1.85%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.15Pre-market26.09.15 22:16
●●●●●●●● ●●●●● ●●●●●●
GT Biopharma has received FDA clearance for its IND application for GTB-5550 to treat multiple myeloma. The initiation of the Phase 1 trial remains contingent upon the receipt of non-dilutive grant funding.…more
$5.51+1.85%vs prev closeShareBenzinga - 9.15Pre-market26.09.15 21:45
●●●●●●●● ●●●●● ●●●●●●
GT Biopharma has secured FDA clearance to initiate human clinical trials for its multiple myeloma treatment candidate, GTB-5550. The start of the trial remains contingent upon the receipt of non-dilutive grant funding.…more
$5.51+1.85%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report